January 16, 2017 Dear Valued Customers and Distributor Partners, Today Bio-Rad Laboratories, Inc. has announced the signing of a definitive agreement to acquire RainDance Technologies, Inc. Please reference the press release. The transaction is subject to the approval of shareholders,
BILLERICA, Mass. — January 16, 2017 — RainDance Technologies, a life sciences tools company, announced today that its Board of Directors has entered into a definitive agreement to sell the company to Bio-Rad Laboratories, Inc. Since its foundation in 2004, RainDance pioneered the de
Droplet-Based Digital PCR: Application in Cancer Research G. Perkins*,†, H. Lu*, F. Garlan*, V. Taly*,1 *Universite Sorbonne Paris Cite, INSERM UMR-S1147, CNRS SNC 5014, Centre Universitaire des Saints-Pe`res, Equipe labelisee LIGUE Contre le Cancer, Paris, France,†European George
RainDance Technologies® is making complex genetics simple. The company’s ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases. Major research institutions and laboratories around the world rely on the performance of RainDance systems. Based outside Boston, Massachusetts, the company supports customers using RainDrop® Digital PCR, as well as the ThunderStorm® and ThunderBolts™ Next-Generation Sequencing Enrichment Systems through its international sales and service operations, as well as a global network of distributors and commercial service providers. Both technology platforms have been recognized by The Scientist as Top 10 Innovations with the RainDrop System winning the award in 2014 and the ThunderStorm System winning the award in 2011.